Drug Trial Radar · NCT03723655
A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM
Last checked: Nov 20, 2026Latest source record: Feb 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
314
Actual
Start
Sep 27, 2018
Primary completion
Jan 16, 2026
Study completion Jan 16, 2026
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Oct 29, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Approximately 30 sites that enrolled participants in the MAVERICK-HCM (MYK-461-006) study in the United States (US) will initiate this study. Approximately 90 sites that enrolled participants in the EXPLORER-HCM (MYK-461-005) study in the US, Europe, and Israel will initiate this study. Note: Approximately 30 centers overlap between MAVERICK and EXPLORER.
Conditions
- Hypertrophic Cardiomyopathy
- Obstructive Hypertrophic Cardiomyopathy
- Non-obstructive Hypertrophic Cardiomyopathy
Interventions
mavacamtenDrug
mavacamten capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency and severity of treatment-emergent adverse events and serious adverse eventsTime frame: 252 weeks
Locations
68 sites in 13 countries. Site status is shown where the registry gives one.
Local Institution - 0045
Scottsdale, Arizona
Local Institution - 0058
Los Angeles, California
Local Institution - 0066
San Francisco, California
Local Institution - 0063
Stanford, California
Local Institution - 0043
New Haven, Connecticut
Local Institution - 0067
Jacksonville, Florida
Local Institution - 0050
Chicago, Illinois
Local Institution - 0070
Indianapolis, Indiana
Local Institution - 0049
Iowa City, Iowa
Local Institution - 0054
Boston, Massachusetts
Local Institution - 0051
Ann Arbor, Michigan
Local Institution - 0074
Grand Rapids, Michigan
Local Institution - 0048
St Louis, Missouri
Local Institution - 0060
New York, New York
Local Institution - 0056
New York, New York
Local Institution - 0071
Charlotte, North Carolina
Local Institution - 0047
Durham, North Carolina
Local Institution - 0052
Cincinnati, Ohio
Local Institution - 0044
Portland, Oregon
Local Institution - 0068
Bethlehem, Pennsylvania
Local Institution - 0046
Philadelphia, Pennsylvania
Local Institution - 0064
Pittsburgh, Pennsylvania
Local Institution - 0073
Memphis, Tennessee
Local Institution - 0061
Dallas, Texas
Local Institution - 0055
Houston, Texas
Local Institution - 0057
Houston, Texas
Local Institution - 0072
Murray, Utah
Local Institution - 0062
Salt Lake City, Utah
Local Institution - 0053
Charlottesville, Virginia
Local Institution - 0059
Richmond, Virginia
Local Institution - 0065
Seattle, Washington
Local Institution - 0002
Aalst, Belgium
Local Institution - 0001
Brussels, Belgium
Local Institution - 0003
Edegem, Belgium
Local Institution - 0010
Prague, Czechia
Local Institution - 0009
Prague, Czechia
Local Institution - 0011
Aarhus, Denmark
Local Institution - 0012
Frederiksberg, Denmark
Local Institution - 0013
Odense, Denmark
Local Institution - 0014
Nantes, France
Showing 40 of 68 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.